Granules India receives 11 observations from Portuguese drug regulator

Infarmed, Portugal, issued these observations for Granules India's Gagillapur facility

Granules India bags exclusive rights for USpharma Windlas' four products

Premium

BS B2B Bureau Hyderabad

Last Updated : Jan 09 2017 | 4:38 PM IST

Granules India Ltd has received eleven observations from Infarmed, the Portuguese drug regulator, for its facility located at Gagillapur, Telangana. These observations were issued by Infarmed after it conducted a renewal inspection on the company's Gagillapur facility, which manufactures pharmaceutical formulation intermediates (PFIs) and finished dosages (FDs).

“The company has initiated necessary and preventive action plan within the stipulated time. It will also be requesting the Infarmed for re-inspection of the Gagillapur facility at the earliest. The company is committed to comply with all the required regulatory requirements and follow the best practices of the industry. The company acknowledges the

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in